Referencia número: HY-10468

NM107

(Synonyms: 2'-C-Methylcytidine)

1 Cited Publications

Revisión del cliente

Based on 1 publication(s) in Google Scholar

NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC₅₀ of NM107 in the wild-type replicon cells is 1.85 μM.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.90%
No. CAS: 20724-73-6
Fòrmula: C₁₀H₁₅N₃O₅
Peso molecular:257.24

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

NM107 Chemical Structure

No. CAS: 20724-73-6

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (1)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC₅₀ of NM107 in the wild-type replicon cells is 1.85 μM^[1]^[2].

IC₅₀ & Target

HCV^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
BHK-21	CC₅₀	>100 μM Compound: 2'-C-methyl-cytidine	Cytotoxicity against BHK21 cells by MTT assay Cytotoxicity against BHK21 cells by MTT assay	[PMID: 22513121]
BHK-21	CC₅₀	>100 μM Compound: 2'-MeCyt	Cytotoxicity against BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 22047799]
BHK-21	CC₅₀	>100 μM Compound: 2'-MeCyt	Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27161176]
BHK-21	CC₅₀	>100 μM Compound: NM 107	Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method	[PMID: 25913116]
BHK-21	EC₅₀	>100 μM Compound: Met-Cyt	Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method	[PMID: 25014745]
BHK-21	EC₅₀	>100 μM Compound: Met-Cyt	Antiviral activity against Reovirus 1 ATCC VR- 214 infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay Antiviral activity against Reovirus 1 ATCC VR- 214 infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay	[PMID: 26479028]
BHK-21	EC₅₀	16 μM Compound: 2'-C-methyl-cytidine	Antiviral activity against Reovirus 1 3651 ATCC VR-214 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus 1 3651 ATCC VR-214 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 22513121]
BHK-21	EC₅₀	16 μM Compound: 2'-MeCyt	Antiviral activity against Reovirus type-1 3651 infected in hamster BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 3651 infected in hamster BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 22047799]
BHK-21	EC₅₀	16 μM Compound: 2'-MeCyt	Antiviral activity against Reovirus type-1 3651 infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 3651 infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 27161176]
BHK-21	EC₅₀	16 μM Compound: Met-Cyt	Antiviral activity against Simian virus 12 3651 (ATCC VR- 214) infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method Antiviral activity against Simian virus 12 3651 (ATCC VR- 214) infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method	[PMID: 25014745]
BHK-21	EC₅₀	6 μM Compound: NM 107	Antiviral activity against Reovirus 1 infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method Antiviral activity against Reovirus 1 infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method	[PMID: 25913116]
CCRF-CEM	CC₅₀	>100 μM Compound: 2'C-MeC	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay	[PMID: 28595015]
CCRF-CEM	CC₅₀	22 μM Compound: 2'-C-Me-C; NM-107	Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay	[PMID: 30653317]
CCRF-CEM	IC₅₀	54.4 μM Compound: NM-107	Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method	[PMID: 22014549]
Huh-5-2	CC₅₀	>33 μM Compound: 2'-C-Methylcytidine	Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay	[PMID: 18625766]
Huh-5-2	EC₅₀	2 μM Compound: 2'-C-Methylcytidine	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay	[PMID: 18625766]
Huh-7	CC₅₀	>10 μM Compound: 2'C-MeC	Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay	[PMID: 28595015]
Huh-7	CC₅₀	>10 μM Compound: NM-107	Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs	[PMID: 22014549]
Huh-7	CC₅₀	>100 μM Compound: 2'-C-Me-C; NM-107	Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay	[PMID: 30653317]
Huh-7	CC₅₀	>100 μM Compound: 2'-C-MeCyd	Cytotoxic concentration against HCV replication RNA levels in Huh7 cells determined by HCV replicon assay Cytotoxic concentration against HCV replication RNA levels in Huh7 cells determined by HCV replicon assay	[PMID: 16107149]
Huh-7	CC₅₀	>100 μM Compound: NM-107	Cytotoxicity against human HuH7 cells Cytotoxicity against human HuH7 cells	[PMID: 18285474]
Huh-7	CC₅₀	>300 μM Compound: 2'-C-Me-C, NM107	Cytotoxicity against human HuH7 cells expressing E2 glycoprotein assessed as reduction of rRNA level after 5 days Cytotoxicity against human HuH7 cells expressing E2 glycoprotein assessed as reduction of rRNA level after 5 days	[PMID: 21621997]
Huh-7	CC₅₀	>33 μM Compound: 2'-C-Me-C	Cytotoxicity against human HuH7 cells after 72 hrs Cytotoxicity against human HuH7 cells after 72 hrs	[PMID: 21880398]
Huh-7	CC₅₀	>50 μM Compound: 2'-C-Me-C	Cytotoxicity against human Huh7 cells assessed as rRNA level after 5 days Cytotoxicity against human Huh7 cells assessed as rRNA level after 5 days	[PMID: 19072694]
Huh-7	CC₅₀	>89 μM Compound: 2'-C-Me C	Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay	[PMID: 22578461]
Huh-7	CC₅₀	>98 μM Compound: 8a, NM-107	Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 3 days by BrdU incorporation assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 3 days by BrdU incorporation assay	[PMID: 24345201]
Huh-7	CC₅₀	>98.4 μM Compound: 1, NM-107	Cytotoxicity against human HuH7 cells expressing CMV-Luc after 3 days by luciferase assay Cytotoxicity against human HuH7 cells expressing CMV-Luc after 3 days by luciferase assay	[PMID: 21033671]
Huh-7	CC₅₀	94.75 μM Compound: 2CMC	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 26988299]
Huh-7	EC₅₀	0.23 μM Compound: NM107	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	0.48 μM Compound: NM107	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	0.62 μM Compound: NM107	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	1 μM Compound: NM107	Antiviral activity against Hepatitis C virus genotype 2a JFH1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus genotype 2a JFH1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	1.1 μM Compound: NM107	Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	1.23 μM Compound: NM-107	Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human HuH7 cells after 3 days by luciferase reporter gene assay Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human HuH7 cells after 3 days by luciferase reporter gene assay	[PMID: 18285474]
Huh-7	EC₅₀	1.3 μM Compound: NM107	Antiviral activity against Hepatitis C virus isolate Con1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	1.7 μM Compound: 2'-C-Me-C, NM107	Antiviral activity against HCV1a infected in human HuH7 cells expressing E2 glycoprotein assessed as inhibition of viral RNA replication after 5 days Antiviral activity against HCV1a infected in human HuH7 cells expressing E2 glycoprotein assessed as inhibition of viral RNA replication after 5 days	[PMID: 21621997]
Huh-7	EC₅₀	11.2 μM Compound: 2CMC	Antiviral activity against Dengue virus 2 DN454009A infected in human HuH7 cells assessed as inhibition of viral RNA level measured 72 hrs post infection by qRT-PCR method Antiviral activity against Dengue virus 2 DN454009A infected in human HuH7 cells assessed as inhibition of viral RNA level measured 72 hrs post infection by qRT-PCR method	[PMID: 26988299]
Huh-7	EC₅₀	1143 nM Compound: NM107	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis	[PMID: 18936191]
Huh-7	EC₅₀	1623 nM Compound: NM107	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis	[PMID: 18936191]
Huh-7	EC₅₀	2.4 μM Compound: 2'-C-Me-C	Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay	[PMID: 21880398]
Huh-7	EC₅₀	2.5 μM Compound: 19	Antiviral activity against HCV genotype 1a infected in human HuH7 cells by replicon based assay Antiviral activity against HCV genotype 1a infected in human HuH7 cells by replicon based assay	[PMID: 25650256]
Huh-7	EC₅₀	2.5 μM Compound: NM107	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	2.8 μM Compound: 19	Antiviral activity against HCV genotype 1b infected in human HuH7 cells by replicon based assay Antiviral activity against HCV genotype 1b infected in human HuH7 cells by replicon based assay	[PMID: 25650256]
Huh-7	EC₅₀	2.8 μM Compound: NM-107	Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR	[PMID: 22014549]
Huh-7	EC₅₀	3.5 μM Compound: 2'-C-Me-C	Antiviral activity against HCV in human Huh7 cells assessed as reduction of viral level after 5 days by RNA subgenomic replicon assay Antiviral activity against HCV in human Huh7 cells assessed as reduction of viral level after 5 days by RNA subgenomic replicon assay	[PMID: 19072694]
Huh-7	EC₅₀	4.07 μM Compound: 2'-C-Me C	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs	[PMID: 22578461]
Huh-7	EC₅₀	4.6 μM Compound: 1, NM-107	Antiviral activity against Hepatitis C virus subtype 1b with adaptive mutations of E1202G, T1280I, K1846T in NS5B polymerase infected in human HuH7 cells assessed as inhibition of viral replication after 3 days by luciferase assay Antiviral activity against Hepatitis C virus subtype 1b with adaptive mutations of E1202G, T1280I, K1846T in NS5B polymerase infected in human HuH7 cells assessed as inhibition of viral replication after 3 days by luciferase assay	[PMID: 21033671]
Huh-7	EC₅₀	4.6 μM Compound: 8a, NM-107	Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay	[PMID: 24345201]
L1210	IC₅₀	12 μg/mL Compound: 17	Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse. Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.	[PMID: 1992123]
MT4	CC₅₀	>98.4 μM Compound: 1, NM-107	Cytotoxicity against human MT4 cells expressing LTR-Luc after 3 days by luciferase assay Cytotoxicity against human MT4 cells expressing LTR-Luc after 3 days by luciferase assay	[PMID: 21033671]
PBMC	CC₅₀	>100 μM Compound: 2'C-MeC	Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay	[PMID: 28595015]
PBMC	CC₅₀	60 μM Compound: 2'-C-Me-C; NM-107	Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay	[PMID: 30653317]
PBMC	IC₅₀	47.4 μM Compound: NM-107	Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method	[PMID: 22014549]
Vero	CC₅₀	>100 μM Compound: 2'C-MeC	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay	[PMID: 28595015]
Vero	CC₅₀	>100 μM Compound: 2'-C-Me-C; NM-107	Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay	[PMID: 30653317]
Vero	EC₅₀	18 μM Compound: 2'-C-methyl-cytidine	Antiviral activity against Human coxsackievirus B5 ATCC VR-29 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining Antiviral activity against Human coxsackievirus B5 ATCC VR-29 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining	[PMID: 26119992]
Vero	EC₅₀	7.3 μM Compound: 2'-C-methyl-cytidine	Antiviral activity against Poliovirus type 1 ATCC VR-1562 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 2 days by crystal violet staining Antiviral activity against Poliovirus type 1 ATCC VR-1562 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 2 days by crystal violet staining	[PMID: 26119992]
Vero	EC₅₀	94 μM Compound: 2'-CMC	Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition virus-induced cell death by MTS assay Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition virus-induced cell death by MTS assay	[PMID: 22310228]
Vero	IC₅₀	>100 μM Compound: NM-107	Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis	[PMID: 22014549]
Vero 76	CC₅₀	>100 μM Compound: 2'-C-methyl-cytidine	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining	[PMID: 26119992]
Vero 76	CC₅₀	16 μM Compound: Met-Cyt	Cytotoxicity against african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 26479028]

In Vitro

NM107 (25 μM; 24 hours; Huh7-1 cells and cell culture-propagated HCV) treatment decreases extracellular viral titers and intracellular RNA levels.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[2]

Cell Line:

Huh7-1 cells and cell culture-propagated HCV (HCVcc)
Concentration:

25 μM
Incubation Time:

24 hours
Result:

Extracellular virus titers declined in parallel with intracellular RNA levels.

Chemical Information

No. CAS 20724-73-6
Appearance Solid
Peso molecular 257.24
Fòrmula C₁₀H₁₅N₃O₅
Color White to off-white
SMILES

OC[C@@H]1[C@@H](O)[C@](O)(C)[C@H](N2C(N=C(N)C=C2)=O)O1
Synonyms

2'-C-Methylcytidine
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Virol J

Identification of Co-29, a 5-cyano-2-thiacetyl aromatic pyrimidinone, as a potential inhibitor targeting the RdRp of norovirus. [Abstract]

2025 Apr 4;22(1):93. PMID: 40186285

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (388.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 50 mg/mL (194.37 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.8874 mL

19.4371 mL

38.8742 mL

5 mM

0.7775 mL

3.8874 mL

7.7748 mL

10 mM

0.3887 mL

1.9437 mL

3.8874 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 50 mg/mL (194.37 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Mathy JE, et al, Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother. 2008 Sep;52(9):3267-75. [Content Brief]

[2]. Guedj J, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.8874 mL	19.4371 mL	38.8742 mL	97.1855 mL
	5 mM	0.7775 mL	3.8874 mL	7.7748 mL	19.4371 mL
	10 mM	0.3887 mL	1.9437 mL	3.8874 mL	9.7186 mL
	15 mM	0.2592 mL	1.2958 mL	2.5916 mL	6.4790 mL
	20 mM	0.1944 mL	0.9719 mL	1.9437 mL	4.8593 mL
	25 mM	0.1555 mL	0.7775 mL	1.5550 mL	3.8874 mL
	30 mM	0.1296 mL	0.6479 mL	1.2958 mL	3.2395 mL
	40 mM	0.0972 mL	0.4859 mL	0.9719 mL	2.4296 mL
	50 mM	0.0777 mL	0.3887 mL	0.7775 mL	1.9437 mL
	60 mM	0.0648 mL	0.3240 mL	0.6479 mL	1.6198 mL
	80 mM	0.0486 mL	0.2430 mL	0.4859 mL	1.2148 mL
	100 mM	0.0389 mL	0.1944 mL	0.3887 mL	0.9719 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

NM107

1 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

NM107

Nucleotide Compound Library

Anti-Hepatitis C Virus Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Anti-Infection Compound Library

Antiviral Compound Library

Publications Citing Use of MedChemExpress (MCE) NM107

Actividad biológica

Chemical Information

Publications (1)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

NM107

Nucleotide Compound Library

Anti-Hepatitis C Virus Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Anti-Infection Compound Library

Antiviral Compound Library

Publications Citing Use of MedChemExpress (MCE) NM107

Actividad biológica

Chemical Information

Publications (1)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

NM107 Related Classifications

HY-10468 Related Classifications